Form 4: Jazz Pharma SVP Sells Shares Under 10b5-1 Plan

Jazz Pharmaceuticals' SVP of Technical Operations, Mary Elizabeth Henderson, sold 2,238 ordinary shares for a weighted average price of $169.511 per share.

Summary

• Mary Elizabeth Henderson, SVP, Technical Operations at Jazz Pharmaceuticals plc (JAZZ), disposed of 2,238 ordinary shares.
• The transaction occurred on December 9, 2025.
• The shares were sold at a weighted average price of $169.511 per share, with individual sales ranging from $169.00 to $169.82.
• The total value of shares sold was approximately $379,409.72.
• Following the transaction, Ms. Henderson beneficially owns 19,508 ordinary shares.
• The sale was executed pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of an insider stock sale, which is a neutral event. The sale was conducted under a pre-arranged 10b5-1 plan, indicating it was not a discretionary sale based on new information.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction disclosure and does not provide specific insights into broader industry trends or competitive landscape. Insider sales, especially those under a 10b5-1 plan, are common for executive compensation and personal financial management.

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan typically has minimal direct impact on shareholders, as it's often for personal financial planning rather than a signal of company performance.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Insider Sale, Form 4, Share Sale, Mary Elizabeth Henderson, 10b5-1 Plan